Sun Pharmaceutical Industries
Growth unavailable
Q2 FY2027 · Period ended 30 Sep 2026
Basis: Consolidated, as stated in the company's press release
Reported revenue (₹ million): Not available
Read summary and comparison caveats
Sun Pharma reported September-quarter consolidated sales of ₹161,000 million, up 11.8%, and EBITDA of ₹47,439 million, up 4.8%. Net profit was ₹19,885 million. The company also reports an adjusted net profit of ₹31,620 million.
- Source: Sun Pharma's press release dated 30 Oct 2026. Values are in ₹ million as printed (₹10 million = ₹1 crore). The release gives growth percentages but no year-ago values, so the changes shown are the company's own and we computed none.
- The release does not explain the gap between net profit and adjusted net profit in the sections we read. Adjusted net profit is the company's own measure. Treat the two as different figures.
- The release is marked consolidated. We did not read the audit or limited-review status.
- This page is a selected set of checked results, not complete market coverage.
Checked 2 Nov 2026
Open original filing